SEHK:1672Biotechs
Is Ascletis Pharma (SEHK:1672) Undervalued As FDA Clears Its ASC35 Obesity Trial?
Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment.
See our latest analysis for Ascletis Pharma.
At a latest share price of HK$11.54, Ascletis Pharma has seen a 7 day share price return of 18.72% and a 30 day share price return of 10.11%. However, the 90 day share price return is down 32.04%. The 1 year total shareholder return of 22.51% and the very large 3...